Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kotra Industries BhdXKLS:0002 83 Debt-to-EBITDA is 0.42 as of Mar. 2026, which is 29% below its 10-year median of 0.59. GuruFocus rates XKLS:0002 with a GF Score™ of 83/100 and a GF Value™ of RM4.35 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 690 Drug Manufacturers companies, Kotra Industries Bhd ranks better than 75.22% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Kotra Industries Bhd's Debt-to-EBITDA or its related term are showing as below:
XKLS:0002'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 0.59 Max: 3.45
Current: 0.39
During the past 13 years, the highest Debt-to-EBITDA Ratio of Kotra Industries Bhd was 3.45. The lowest was 0.01. And the median was 0.59.
XKLS:0002's Debt-to-EBITDA is ranked better than 75.22% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.65
vs XKLS:0002: 0.39
Kotra Industries Bhd (XKLS:0002) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Kotra Industries Bhd Debt-to-EBITDA Related Terms
Kotra Industries Bhd Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Kotra Industries Bhd's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0002 vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kotra Industries Bhd's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kotra Industries Bhd Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kotra Industries Bhd's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kotra Industries Bhd's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Kotra Industries Bhd (XKLS:0002) has a Debt-to-EBITDA of 0.42 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Kotra Industries Bhd. This is 29% below median its historical median of 0.59. Over the past decade, Kotra Industries Bhd's Debt-to-EBITDA has ranged from 0.01 to 3.45. According to the industry distribution chart, Kotra Industries Bhd ranks #171 out of 690 companies in the Drug Manufacturers industry, placing it in the top 24.8%.
Is Kotra Industries Bhd's Debt-to-EBITDA too high?
Kotra Industries Bhd's current Debt-to-EBITDA of 0.42 is 29% below median its 10-year median of 0.59. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 3.45. The Drug Manufacturers industry median Debt-to-EBITDA is 1.65. Kotra Industries Bhd's value of 0.42 is 74.5% below this industry median. Based on the distribution chart, Kotra Industries Bhd ranks #171 out of 690 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kotra Industries Bhd has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kotra Industries Bhd's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kotra Industries Bhd ranks #171 out of 690 companies for Debt-to-EBITDA. This places Kotra Industries Bhd in the top 25% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.65. Kotra Industries Bhd's value of 0.42 is 74.5% below this benchmark. Historically, Kotra Industries Bhd's own Debt-to-EBITDA has ranged from 0.01 to 3.45 over the past decade. While the company's 10-year median is 0.59 vs. the industry median of 1.65, Kotra Industries Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kotra Industries Bhd's current Debt-to-EBITDA of 0.42 is 74.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Kotra Industries Bhd. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kotra Industries Bhd's current Debt-to-EBITDA is 0.42, which is 29% below median its own 10-year median of 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kotra Industries Bhd stock overvalued right now?
Based on GuruFocus' analysis, Kotra Industries Bhd (XKLS:0002) is currently considered Modestly Undervalued. The stock's GF Value™ is RM4.35, compared to a current price of RM3.75 — trading 13.8% below its estimated fair value. The current Debt-to-EBITDA is 0.42, which is 29% below median its 10-year median of 0.59 and 74.5% below the Drug Manufacturers industry median of 1.65. Kotra Industries Bhd's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Kotra Industries Bhd (XKLS:0002), the current Debt-to-EBITDA is 0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kotra Industries Bhd (XKLS:0002) Overvalued in 2026?
Based on GuruFocus' analysis, Kotra Industries Bhd stock appears to be undervalued.
The current stock price of RM3.75 is trading 13.8% below its estimated GF Value™ of RM4.35.
GuruFocus considers Kotra Industries Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0002:
Debt-to-EBITDA: 0.42 (29% below median its 10-year median of 0.59)
GF Value™: RM4.35 vs. price of RM3.75 (13.8% below fair value)
Industry Position: 74.5% below the Drug Manufacturers median (#171 of 690)
No single metric tells the full story. See the XKLS:0002 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kotra Industries Bhd is a Malaysian pharmaceutical company engaged in the development, manufacturing, and supply of pharmaceutical and healthcare products supporting all life stages. Its portfolio includes life-saving medicines, OTC supplements, and nutrition products. The Group markets three core brands: Appeton, offering health supplements and nutrition across all age groups; Vaxcel, providing injectable medicines for infectious diseases, kidney care, and gastroenterology; and Axcel, specializing in oral and topical medicines for paediatrics, dermatology, and infectious diseases. The company operates in Malaysia and overseas, with the majority of revenue derived from Malaysia.
83GF Score
Get the complete analysis for XKLS:0002
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0002 has been successfully added to your 
